

Emyria and UWA expand unique MDMA-inspired analogue library

HIGHLIGHTS

Emyria, and partner the University of Western Australia, have shipped their **fourth batch of 14 unique MDMA analogues** for safety screening with Eurofins (EPA:ERF)

Unique library now exceeds **140** proprietary, neurologically active compounds

In addition, an initial priority set of 5 compounds has been sent to **PsychoGenics** in the USA to commence advanced preclinical screening (See ASX release 19 Sep 2022)

Additional metabolic studies have also commenced with an Australian CRO to help evaluate the half-lives of a priority set of compounds in mice, rat and human liver cells

A recording of a recent webinar outlining the MDMA-inspired drug discovery program is available here: <https://investorhub.emyria.com/> (See ASX release 13 Oct 2022)

Emyria Limited (ASX: EMD) (Emyria or the Company), a clinical stage biotech focussed on neuroscience and mental health, is pleased to announce positive progress of its preclinical MDMA-inspired drug discovery program with partner, the University of Western Australia and led by medicinal chemistry expert, Dr Matt Piggott.

Emyria and UWA have been actively growing and screening a unique drug-discovery pipeline of novel MDMA analogues to identify new chemical entities and drug candidates with the potential to address major unmet needs in mental health and neurological disorders. Emyria previously secured exclusive rights to all MDMA-like compounds created under the partnership with Prof. Piggott and UWA. (See ASX announcement 05 Aug 2021)

Additional compound synthesis and screening is ongoing and a fourth batch of 14 unique compounds, inspired by previous screening results, was recently prepared and shipped for preliminary screening with Eurofins. This brings the total number of unique compounds in the library to over 140.

5 high priority compounds have been shipped to the USA for evaluation with specialist neuroscience CRO, PsychoGenics and additional metabolic studies have commenced with an Australian CRO to help determine the metabolic half-life of a priority set of compounds.

This announcement has been approved and authorised for release by the CEO of Emyria.

FOR FURTHER INFORMATION

Dr. Michael Winlo
Managing Director
+61 (0) 8 6559 2800
mwinlo@emyria.com

Lexi O'Halloran
Investor Relations
+61 (0) 404 577 076
investors@emyria.com

Andrew Williams
Media Relations
+61 (0) 416 583 672
awilliams@emyria.com

Sufian Ahmad
Corporate Advisor
+61 (0) 412 316 162
info@62capital.com.au

DRUG DEVELOPMENT

CLINICAL PROGRAMS
Ultra-Pure cannabinoid delivery platform

NEW DRUG DISCOVERY

PRE-CLINICAL PROGRAM
MDMA-like analogues

EMD-RX5 "direct-to-consumer"	
Formulation optimisation	✓
Phase 1 study	✓
Ethics approved for Phase 3	✓
Phase 3 commencement	✓
Regulatory submission	
Commercial strategy Australia	
Commercial strategy Europe	
Commercial strategy USA	

EMD-RX7 "prescription medicine"	
Formulation optimisation	✓
Phase 1	
Pre-IND (FDA)	
Pivotal trials	

MDMA-like drug development	
Continuous creation & screening	✓
First patent family filed	✓
US-focussed preclinical program	✓
Metabolic studies	✓
Preclinical assays (multiple animal models)	✓
Human cell line assays	✓
Advanced assay development	
Lead selection	
Phase 1 trials	
Global commercial strategy	

ABOUT EMYRIA | emyria.com

Emyria Limited is a clinical drug development and care delivery company focused on accelerating drug development and improving patient outcomes in neuroscience and mental health via:

- **Drug Development:** Emyria has developed an Ultra-Pure cannabinoid platform that can support the registration of multiple proprietary dose forms. Emyria's first dose form, EMD-RX5 is in Phase 3 trials
- **New Drug Discovery:** Inspired by MDMA, Emyria is developing one of the world's largest libraries of MDMA-like compounds with partner, the University of Western Australia.
- **Proprietary Real-World Data (RWD):** Emyria gathers ethically-sourced data with patients cared for at Emyria's own specialist clinical service (Emerald Clinics). Emyria RWD can help support drug development and care model improvement.

EMYRIA'S

[Investorhub.emyria.com](https://investorhub.emyria.com)

INTERACTIVE

Interact with Emyria's announcements and updates by asking questions and comments, which our team can respond to where possible.

INVESTOR

HUB

CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.